Donidalorsen
Donidalorsen is an antisense oligonucleotide (ASO)-GalNAc conjugate designed to reduce plasma kallikrein activity by degrading prekallikrein (PKK) mRNA, thereby decreasing bradykinin production. It is used for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling. By targeting the kallikrein-bradykinin pathway, donidalorsen helps prevent or reduce the frequency and severity of HAE attacks.
Donidalorsen is an ASO therapy that treats hereditary angioedema by reducing plasma kallikrein activity through targeted mRNA degradation, decreasing bradykinin-mediated swelling attacks.
Key facts at a glance
- ATC
- B06AC09
- RxNorm
- 2724361
- Generic
- Donidalorsen
- Class
- atc-b06
- Brands
- Dawnzera
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Donidalorsen is indicated for the routine prevention of hereditary angioedema (HAE) attacks in adults and adolescents. HAE is caused by C1 inhibitor deficiency or dysfunction, leading to uncontrolled plasma kallikrein activity and excessive bradykinin release, which causes painful and potentially life-threatening swelling episodes affecting the airways, extremities, face, and abdomen.
Donidalorsen is an ASO conjugated to GalNAc (N-acetylgalactosamine), which facilitates targeted delivery to hepatocytes. Once inside cells, it binds to prekallikrein (PKK) messenger RNA (mRNA) and recruits RNase H1 to cleave and degrade the mRNA, preventing translation into PKK protein. Reduced PKK levels decrease plasma kallikrein activity, which in turn reduces bradykinin generation and prevents angioedema attacks.
Donidalorsen is administered via subcutaneous injection. Common adverse reactions may include injection site reactions. As with other ASO therapies, liver function monitoring may be required. Safety and efficacy in pediatric patients under 12 years have not been established. Patients should have a documented diagnosis of HAE before initiating therapy. Emergency treatment for acute HAE attacks should still be available.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy